Peptide research profile

Semaglutide

Also known as GLP-1 analogue · Ozempic · Wegovy · Rybelsus

A long-acting GLP-1 receptor agonist with extensive human trial data and regulated indications for type 2 diabetes, chronic weight management, and selected cardiovascular-risk reduction.

  • Metabolic research
Established human evidence2 referencesEducational use

Dosing literacy

Dosing & scaling, explained

Semaglutide has indication-specific clinical titration schedules. The ladder below describes the subcutaneous obesity regimen studied in STEP and reflected in regulated labeling; it is not individualized prescribing advice. This is educational source context—not a protocol or recommendation.

Scaling framework

How sourced amounts are organized

  1. Initiation0.25 mg / week
    Weeks 1–4

    A tolerability step, not the maintenance exposure used for obesity outcomes.

  2. Escalation0.5 → 1.0 → 1.7 mg / week
    Usually 4 weeks per step

    Stepwise escalation was used before reaching the obesity maintenance dose.

  3. Trial maintenance2.4 mg / week
    Through week 68 in STEP 1

    The STEP 1 maintenance exposure; diabetes products and indications use different maximums.

Milligrams are drug mass. Pen clicks or syringe units cannot be inferred without the labeled concentration.

Schedule literacy

Patterns described in source material

  • Once weekly

    Clinical subcutaneous products are designed for weekly administration.

  • Four-week steps

    The STEP escalation increased exposure approximately every four weeks.

  • Product-specific

    Missed-dose, delay, and intolerance instructions come from the exact regulated product label.

Clinical context
  • 0.25 → 2.4 mg · Once weeklySTEP 1 fixed escalation68-week obesity trial

Human dosing is well studied, but the correct regimen is product- and indication-specific.

Research best practices

Storage, handling and interpretation

Lyophilized material

Keep cold, dry, and protected from light according to the manufacturer certificate or validated lab SOP.

After reconstitution

Use sterile technique, refrigerate as validated, and avoid repeated freeze–thaw cycles.

Traceability

Record lot, concentration, preparation date, and the identity/purity documentation used by the lab.

Research orientation

What researchers are exploring

These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.

  • 01

    Glucose regulation

    Large phase 3 programs evaluate HbA1c and other glycaemic endpoints in type 2 diabetes.

  • 02

    Weight management

    The STEP program studies once-weekly 2.4 mg alongside lifestyle intervention.

  • 03

    Cardiovascular outcomes

    Outcome trials examine major cardiovascular events in high-risk populations.

  • 04

    Dose escalation

    Clinical regimens escalate gradually to improve gastrointestinal tolerability.

Evidence map

What the current evidence can support

Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.

  • Human

    Large randomized trial programs

    Multiple phase 3 trials establish efficacy and characterize common gastrointestinal adverse effects for regulated products.

  • Human

    STEP 1 obesity trial

    In 1,961 adults without diabetes, 2.4 mg once weekly plus lifestyle intervention was compared with placebo for 68 weeks.

  • Review

    Indication-specific interpretation matters

    Diabetes, obesity, cardiovascular, and oral-formulation evidence use different doses, populations, and product instructions.

Recorded protocol library

Amounts recorded for Semaglutide

These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.

  • 01

    STEP 1 initiation step

    0.25 mg

    Sign in for schedule, duration and source context.

  • 02

    STEP 1 escalation step

    1 mg

    Sign in for schedule, duration and source context.

  • 03

    STEP 1 target arm

    2.4 mg

    Sign in for schedule, duration and source context.

Technical reference

Identity, limitations and unknowns

Molecular profile

Class
Acylated GLP-1 receptor agonist
Amino acids
31
Approx. MW
4113.6 Da
Origin / design
Engineered GLP-1 analogue with albumin binding for once-weekly exposure

Important limitations

  • Approved dosing depends on the exact product, indication, comorbidities, and prescribing information.
  • Compounded or research-vial material is not interchangeable with an approved prefilled product.
  • A calculator preset is a recorded research convention, not a recommendation or evidence of clinical benefit.
  • Identity, purity, sterility, and stability can vary substantially outside regulated manufacturing.
  • Route, formulation, and population can make results from one study inapplicable to another use.

Curated sources

2 curated references

  1. Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine · 2021 · Human
  2. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine · 2016 · Human

Related profiles